3 ms·
There is very little competition by design in the US pharmaceutical market, so indeed, it contains many of the worst parts of private industry without the typic
by dmix 10y ago
There is very little competition by design in the US pharmaceutical market, so indeed, it contains many of the worst parts of private industry without the typical benefits of markets.
Just like the recent issue of EpiPen pricing, people (including the next likely president) spread the myth it was the result of a lack of regulation even though a single competitor, and there were many who tried to compete, would have made such a large swing towards high pricing a near self-destructive act for any company: http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-drugs-vs-chairs/ http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-dr...
The question is not whether or not the market is too free but whether or not to put the final bullet in one the last remaining freedoms of the pharmaceutical market at the costs of reduced R&D and fewer new drugs: http://www.ibtimes.com/should-government-control-price-prescription-drugs-2112771 http://www.ibtimes.com/should-government-control-price-presc...